Phase 3 Migraine Trial of DHE in Nasal Form Fails to Show Significant Difference
A formulation of dihydroergotamine (DHE) in a nasal powder form was no different than placebo for relief from pain and annoying symptoms at 2 hours post dose.
An effort to create a treatment for acute
In a
The company said the drug was well tolerated, with no reports of serious adverse events and low adverse event rates. Topline data showed numerical differences vs placebo for both dosages, and the company said both dosages were significantly better than placebo at 3 hours post administration and at later times.
The president and CEO of Satsuma, John Kollins, said the firm was “surprised and disappointed” at the results and that the company would be continuing the analysis of trial data and considering its future business plans. Satsuma said it had cash, cash equivalents, and marketable securities of $93.7 million as of June 30, 2020.
The phase 3 EMERGE efficacy trial is a multicenter, single-dose, randomized, double-blind, placebo-controlled, parallel group US study with more than 1140 patients.
Participants were randomized (1:1:1) to receive 1 of 3 treatments: DHE 3.9 mg, DHE 5.2 mg, or matching placebo to use during their next migraine attack of at least moderate pain severity. The trial was statistically designed for greater than 99% power for the freedom-from-pain end point and greater than 95% power for the freedom-from-most-bothersome-symptom endpoint.
DHE is a derivative of ergotamine. A
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Incorporating Discussions of Cannabis Use Into Oncology Care Visits
September 15th 2024
- Using Cannabis as a Bridge for Symptom Management in Cancer
August 22nd 2024
- Discoveries on Temperature and Touch Win Nobel in Medicine
October 4th 2021
- The Top 5 Most-Read Pain Management Stories of 2020
December 30th 2020
- Dr Wayne Jonas Discusses Emerging Therapies for Pain Management
December 26th 2020